BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8589539)

  • 1. Simultaneous control of measles and rubella by multidose vaccination schedules.
    Becker NG; Rouderfer V
    Math Biosci; 1996 Jan; 131(1):81-102. PubMed ID: 8589539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to measles-mumps-rubella vaccine in children on dialysis.
    Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
    Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Watson JC; Hadler SC; Dykewicz CA; Reef S; Phillips L
    MMWR Recomm Rep; 1998 May; 47(RR-8):1-57. PubMed ID: 9639369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.
    Böttiger M; Christenson B; Romanus V; Taranger J; Strandell A
    Br Med J (Clin Res Ed); 1987 Nov; 295(6608):1264-7. PubMed ID: 3120971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of two-dose vaccination schedules: availability for vaccination and catch-up strategies.
    Rouderfer V; Becker NG
    Math Biosci; 1995 Sep; 129(1):41-66. PubMed ID: 7670225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
    Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
    Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A field trial of combined measles-mumps-rubella vaccine. Satisfactory immunization with 188 children in Chile.
    Borgoño JM; Greiber R; Solari G; Concha F; Carrillo B; Hilleman MR
    Clin Pediatr (Phila); 1973 Mar; 12(3):170-2. PubMed ID: 4701464
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.
    Peltola H; Karanko V; Kurki T; Hukkanen V; Virtanen M; Penttinen K; Nissinen M; Heinonen OP
    Lancet; 1986 Jan; 1(8473):137-9. PubMed ID: 2867355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles-rubella mass immunization campaign in Albania, November 2000.
    Bino S; Kakarriqi E; Xibinaku M; Ion-Nedelcu N; Bukli M; Emiroglu N; Uzicanin A
    J Infect Dis; 2003 May; 187 Suppl 1():S223-9. PubMed ID: 12721917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.